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doi:10.101Efficacy of Rituximab in the Setting
of Steroid-Refractory Chronic Graft-versus-Host
Disease: A Systematic Review and Meta-Analysis
Mohamed A. Kharfan-Dabaja,1,2 Asmita R. Mhaskar,3 Benjamin Djulbegovic,2,3,4
Corey Cutler,5 Mohamad Mohty,6 Ambuj Kumar3,4Increased insight into the role of B lymphocytes in the pathophysiology of graft-versus-host disease has led to
a number of studies assessing the efficacy of the anti-CD20 monoclonal antibody (mAb) rituximab in treating
steroid-refractory chronic graft-versus-host disease (cGVHD). Findings vary greatly among these studies,
however. We conducted a systematic review to summarize the totality of evidence on the efficacy of ritux-
imab in steroid-refractory cGVHD. We performed a PubMed search and contacted experts in the field to
identify relevant studies. Endpoints included overall response rate (including organ-specific) and ability of rit-
uximab to allow dosage reduction of immunosuppressive therapies. Data were pooled under a random-ef-
fects model. Seven studies (3 prospective and 4 retrospective, with a total of 111 patients) met the inclusion
criteria. The pooled proportion of overall responsewas 0.66 (95% confidence interval5 0.57 to 0.74). There
was no heterogeneity among the pooled studies. Response rates were 13% to 100% for cGVHD of the skin,
0 to 83% for cGVHD of the oral mucosa, 0 to 66% for cGVHD of the liver, and 0 to 38% for cGVHD of the
lung. Common adverse events were related to infusion reactions or infectious complications. The relatively
small number of patients and the varying criteria for reporting organ response and dosage reduction of ste-
roids, among other limitations, hinders our ability to reach definitive conclusions on the overall efficacy of
rituximab for cGVHD involving other organs.
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Chronic graft-versus-host disease (cGVHD) rep-
resents one of the most challenging sequelae of alloge-
neic hematopoietic cell transplantation (allo-HCT),
resulting in significant long-term morbidity and
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6/j.bbmt.2009.04.003allo-HCTs using alternate donors, particularly
HLA-mismatched donors, is further increasing the in-
cidence of cGVHD [1,2]. The increasing use of mobi-
lized peripheral blood stem cells (PBSC) as the graft
source also is contributing to the increasing prevalence
of cGVHD [1-3].
A recently released National Institutes of Health
(NIH) working group report on criteria for clinical tri-
als in cGVHD provides standardized criteria for diag-
nosis of cGVHD and an improved scoring system that
better describes the extent and severity of cGVHD for
each organ, taking into account the importance of pre-
serving function [4]. Similarly, expert consensus opin-
ion has resulted in the establishment of more practical
criteria aimed at assessing the therapeutic response in
patients with cGVHD more objectively [5]. Unfortu-
nately, however, treatment outcomes for cGVHD
remain disappointing. Systemic corticosteroid therapy
is the most commonly used first-line treatment for
patients with established cGVHD, but long-term cor-
ticosteroid use is limited by the increased risk of infec-
tion, which remains the leading cause of death in
cGVHD [6]. There is no consensus regarding the
best treatment option for patients with cGVHD who1005
1006 Biol Blood Marrow Transplant 15:1005-1013, 2009M. A. Kharfan-Dabaja et al.do not respond to or progress after corticosteroid ther-
apy. Encouraging responses have been reported using
extracorporeal photopheresis [7,8], mycophenolate
mofetil (MMF) [9,10], and low-dose methotrexate
(MTX), among other modalities [11].
Advances in the understanding of cGVHD have
implicated B lymphocytes in the pathophysiology of
cGVHD.Miklos et al. [12] demonstrated a correlation
between cGHVD and development of antibody re-
sponses to H-Y minor histocompatibility antigens in
cases of sex-mismatched (male recipients with female
donors) allo-HCT. These findings provided the scien-
tific rationale for a number of studies exploring rituxi-
mab to treat patients with steroid-refractory cGVHD.
These studies yielded varying findings regarding or-
gan-specific responses, however. Consequently, we
performed a systematic review to evaluate the totality
of evidence regarding the efficacy of rituximab in treat-
ing steroid-refractory cGVHD.METHODS
Literature Search
We searched the Medline (Pubmed) database us-
ing a broad search strategy to identify prospective or
retrospective studies evaluating the efficacy of ritux-
imab in patients with steroid-refractory cGVHD.
The search was conducted using following terms:
‘‘Rituximab’’[Substance Name] AND ‘‘Graft vs. Host
Disease’’[MeSH]. Relevant references in each ob-
tained article were scanned to identify other relevant
studies. In addition, experts in the field were ap-
proached for unpublished data or to identify addi-
tional studies in the subject area. No search limits
were applied.Inclusion Criteria
All prospective studies evaluating the efficacy of
rituximab in cGVHD were included regardless of the
number of patients enrolled. Retrospective studies
were included if they evaluated the efficacy of rituxi-
mab in cGVHD in a minimum of 5 patients. Single
case reports were excluded.Study Selection, Quality Assessment, and Data
Extraction
Two reviewers (A.M. and A.K.) appraised the list
of references and selected the studies in consultation
with other reviewers (M.K.D. and C.C.). Disagree-
ments were resolved by consensus. Two reviewers
(A.M. and A.K.) independently extracted the data
from selected articles. Data were extracted on specific
clinical outcomes (benefits and harms), as well as on
the methodological quality of the studies.Data Analysis and Statistical Methods
For the purpose of meta-analysis, the proportions
were first transformed into a quantity according to
the Freeman-Tukey variant of the arcsine square
root transformed proportion [13]. The pooled propor-
tion was calculated as the back-transform of the
weighted mean of the transformed proportions, using
a random-effects model [14].
A formal statistical test for heterogeneity using an
I2 test was performed [15]. The heterogeneity and ro-
bustness of the findings also were evaluated through
additional sensitivity analyses. The possibility of pub-
lication bias was assessed using the Begg and Egger
funnel plot method [16]; although this method has
some limitations, it is widely used to assess publication
bias [17]. The meta-analysis was performed using
StatsDirect software (StatsDirect Ltd, Altrincham,
Cheshire, UK). The work was performed ion accor-
dance with the guidelines promulgated at the Quality
of Reporting of Meta-Analyses conference [15].RESULTS
Identification of Studies
Figure 1 summarizes the process used to identify
and select the studies for the systematic review. The
initial search yielded 37 articles, of which 31 were
excluded for the reasons shown in Figure 1. Of the 6
studies that met the inclusion criteria, 3 were catego-
rized as prospective studies and 3 were retrospective
analyses. One retrospective case series was identified
through expert contact [18]. We found no randomized
controlled trials evaluating the efficacy of rituximab
versus other therapeutic alternatives for treating ste-
roid-refractory cGVHD.Methodological Quality of Studies
We conducted a critical appraisal of the methodo-
logical quality of all studies.
Prospective Studies
Unclear reporting of sampling procedures makes it
difficult to determine whether the study sample con-
sisted of consecutive series of patients or a convenient
sampling method was used, possibly introducing a se-
lection or an ascertainment bias that could potentially
plague observational studies.
Retrospective Studies
Whether an analysis addressed a priori hypothesis
or was a result of some post hoc observation was un-
clear. In addition, the relatively small sample sizes
(range, 8 to 38 patients) limited our ability to draw de-
finitive conclusions from these studies.
Number of studies 
retrieved from
PubMed and
manually
N=37   
Studies 
included in the 
final analysis
N=7 
(one added as 
per suggestion 
from an expert)
Excluded N=31
Case reports <5 patients 
(N=6)
Editorial (N=1)
Not GVHD (N=13)
Not refractory GVHD (N=3)
Not rituxan therapy (N=3)
Review article (N=5)
Retrospective 
studies with>5
patients (N=4) 
Prospective 
studies (N=3) 
Figure 1. Identification and selection of studies.
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A Begg and Egger funnel plot showed a symmetric
distribution, indicating the absence of a publication
bias for all of the outcomes assessed here (results not
shown).Outcomes
Mortality
Mortality data were extractable from all 7 studies
[18-24]. The pooled proportion of mortality from 7
studies involving 111 patients was 0.158 (95% confi-
dence interval [CI]5 0.083 to 0.253) (Fig 2A). There
was no statistically significant heterogeneity among
the studies (I25 32.7%; P5 .178). The pooled pro-
portion of mortality was 0.122 (95% CI5 0.034 to
0.253) in 3 prospective studies involving 37 patients
[19,20,22] and 0.158 (95%CI5 0.08 to 0.252) in 4 ret-
rospective studies evaluating 74 patients [18,21,23,24].
Overall Response Rate
Overall response rate (ORR) data were extract-
able from 6 studies involving a total of 108 patients(Fig 2B) [18-21,23,24]. The pooled proportion of
ORR was 0.66 (95% CI5 0.57 to 0.74), and
there was no statistically significant heterogeneity
among the studies (I25 0%; P5 .90). The pooled
proportion of ORR was 0.70 (95% CI5 0.54 to
0.83) in 2 prospective studies evaluating 34 pa-
tients [19,20] and 0.64 (95% CI5 0.53 to 0.74)
in 4 retrospective studies involving 74 patients
[18,21,23,24].Organ-Specific Response
Skin cGVHD
Data on cutaneous cGVHD were extractable from
6 studies involving a total of 67 patients [18,19,21-24].
The pooled proportionORRwas 0.60 (95%CI5 0.41
to 0.78) (Fig 2C). There was a statistically significant
heterogeneity among the pooled studies (I25 60%;
P5 .03). The pooled proportion ORR was 0.85
(95% CI5 0.59 to 0.98) in 2 prospective studies en-
rolling 9 patients [19,22] and 0.51 (95% CI5 0.308
to 0.717) in 4 retrospective studies involving 58 pa-
tients [18,21,23,24].
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.66 (0.57, 0.74)
von Bonin et. al; 2008 0.69 (0.39, 0.91)
Ratanatharathorn et. al; 2003 0.50 (0.16, 0.84)
Canninga-van Dijk et al; 2004 0.83 (0.36, 1.00)
Cutler et. al., 2006 0.68 (0.48, 0.84)
Zaja et. al., 2007 0.66 (0.49, 0.80)
Mohty et. al., 2008 0.67 (0.38, 0.88)
Proportion (95% confidence interval)
Proportion meta-analysis plot for the outcome of overall response Proportion meta-analysis plot for the outcome of survival
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.158 (0.083, 0.253)
von Bonin et. al; 2008 0.077 (0.002, 0.360)
Ratanatharathorn et. al; 2003 0.000 (0.000, 0.369)
Canninga-van Dijk et al; 2004 0.000 (0.000, 0.459)
Cutler et. al., 2006 0.107 (0.023, 0.282)
Okamoto et. al., 2006 0.333 (0.008, 0.906)
Zaja et. al., 2007 0.211 (0.096, 0.373) 
Mohty et. al., 2008 0.333 (0.118, 0.616) 
Proportion (95% confidence interval)
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.606 (0.412, 0.784)
von Bonin et. al; 2008 0.556 (0.212, 0.863)
Ratanatharathorn et. al; 2003 0.125 (0.003, 0.527)
Canninga-van Dijk et al; 2004 0.833 (0.359, 0.996)
Okamoto et. al., 2006 1.000 (0.292, 1.000)
Zaja et. al., 2007 0.607 (0.406, 0.785)
Mohty et. al., 2008 0.692 (0.386, 0.909)
Proportion (95% confidence interval)
Proportion meta-analysis plot for the outcome of skin response
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.29 (0.12, 0.51)
von Bonin et. al; 2008 0.00 (0.00, 0.71)
Ratanatharathorn et. al; 2003 0.00 (0.00, 0.98)
Canninga-van Dijk et al; 2004 0.40 (0.05, 0.85)
Okamoto et. al., 2006 0.00 (0.00, 0.84)
Zaja et. al., 2007 0.21 (0.05, 0.51)
Mohty et. al., 2008 0.67 (0.30, 0.93)
Proportion (95% confidence interval)
Proportion meta-analysis plot for the outcome of Liver response
A B
C D
Figure 2. Forest plot for the outcomes of survival, overall response and organ specific response (skin and liver). The summary effect estimate (pro-
portion) for individual studies are indicated by black rectangles (the size of the rectangle is proportional to the study weight), with the lines representing
95% confidence intervals (CIs). The overall summary effect estimate (proportion) and 95% CI are indicated by the diamond.
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Data on cGVHD of the oral mucosa were extract-
able from 5 studies involving a total of 46 patients
[18-20,22,24]. The pooled proportion of ORR was
0.36 (95% CI5 0.12 to 0.65). There was a statistically
significant heterogeneity among the included studies
for this outcome (I25 73%; P5 .0046). The pooled
proportion of oral cGVHD response was 0.26 (95%
CI5 0.007 to 0.84) in 3 prospective studies involving
15 patients [19,20,22] and 0.45 (95% CI5 0.29 to
0.62) in 2 retrospective studies involving 31 patients
[18,24].
Liver cGVHD
ORR data for the outcome of liver cGVHD were
extractable from 6 studies involving a total of 34 pa-
tients [18,19,21-24]. The pooled proportion of ORR
was 0.29 (95% CI5 0.12 to 0.51) (Fig 2D). There
was no statistically significant heterogeneity among
the pooled studies for this outcome (I25 41.8%;
P5 .126). The pooled proportion ORR was 0.28
(95%CI5 0.03 to 0.64) in 2 prospective studies enroll-
ing 7 patients [19,22] and 0.29 (95%CI5 0.06 to 0.59)
from 4 retrospective studies involving 27 patients
[18,21,23,24].
Gastrointestinal cGVHD
Data on response rate for gastrointestinal (GI)
cGVHD were reported in 4 studies (1 prospectiveand 3 retrospective) involving a total of 12 patients
[18,21,22,24]. The pooled proportion ORR was 0.31
(95%CI5 0.07 to 0.62). There was no statistically sig-
nificant heterogeneity among the pooled studies
(I25 35.7%; P5 .19). One prospective study showed
no response to rituximab treatment in 1 patient with
steroid-refractory gastrointestinal cGVHD [22]. The
pooled proportion ORR in 3 retrospective studies in-
volving 11 patients was 0.346 (95% CI5 0.05 to
0.72) [18,21,24].
Lung cGVHD
Data on response rates in cases of steroid-refrac-
tory cGVHD involving the lung were extractable
from 4 studies involving a total of 15 patients [18,22-
24]. In 1 prospective study, rituximab produced no re-
sponse [22]. The pooled proportion of lung cGVHD
response in 3 retrospective studies involving 14 pa-
tients was 0.30 (95% CI5 0.11 to 0.53) [18,23,24].
There was no significant heterogeneity among the
pooled studies (I25 0%; P5 .58).
Other Organs with cGVHD
Reponses to rituximab also were reported in pa-
tients with steroid-refractory ocular cGVHD, with
rates ranging from 13% (1/8) to 38% (6/16) [23,24],
and in patients with steroid-refractory cGVHD of
the musculoskeletal system, with response rates of
100% (1/1) and 75% (3/4) [18,23].
Biol Blood Marrow Transplant 15:1005-1013, 2009 1009Rituximab in Steroid-Refractory Chronic GVHDDoes Administration of Rituximab Allow
Reduction (or Discontinuation)
of Immunosuppressive Therapies, Including
Corticosteroids?
Administration of rituximab facilitates dosage
reduction of previous immunosuppressive therapies
in patients with refractory cGVHD. Zaja et al. [24]
reported a median dosage reduction of immunosup-
pressive therapy (including corticosteroids) of 82%
(range, 0 to 100%), mostly in cases of steroid-refrac-
tory cGVHD involving the skin and oral mucosa.
Two studies specifically addressed the glucocorti-
coid-sparing effect of rituximab in patients with ste-
roid-refractory cGVHD. Mohty et al. [21] reported
a median glucocorticoid dosage reduction of 86%
(range, 0 to 100%) in 11 of 15 patients (73%) treated
with rituximab; this steroid sparing-effect also was
more pronounced in skin and oral mucosal cGVHD,
consistent with a previous report [24]. Similarly, Cut-
ler et al. [20] reported a 75%median dosage reduction
of prednisone (from 40 mg to 10 mg) in more than
two-thirds of their patients. These and other studies
are summarized in Table 1.
Treatment-Related Morbidity and Mortality
(TRM)
Rituximab appears to be relatively well tolerated,
with side effects related mainly to infusion reactions
(5% to 11%) and infectious complications, including
sepsis (3% to 33%), pneumonia (8% to 33%), viral
conjunctivitis (5%), diarrhea (14%), and herpes zoster
reactivation (33%; 1/3), among others [18-24]. Long-
term toxicities related to treatment were not reported
[18-24].
None of the studies, prospective or retrospective,
reportedmortality attributable to rituximab treatment.
Sensitivity Analyses
Because of the limited number of prospective stud-
ies available, as well as the relatively small number ofTable 1. Dose Reduction of Immunosuppressive or Corticosteroid
Author, Year
Median Do
Reduction(Ra
Von Bonin et al., 2008 [18] NR
Mohty et al., 2008 [21] 86% (33%-100
Zaja et al., 2007 [24] 82% (0-100%)†
Okamoto et al., 2006 [22] NE‡
Cutler et al., 2006 [20] 75% (NE)
Canninga-Van Dijk et al., 2004 [19] NE
Ratanatharathorn et al., 2003 [23] NR (68.75%-87
NR indicates not reported; NE, not extractable; NA, not available.
*Updated data were provided by the authors (Cutler et al., CS).
†Zaja et al. reported organ-specific dose reduction; the numbers given here a
response.
‡Okamoto et al. reported no change in the dose of immunosuppressive drugs
§Ratanatharathorn et al. reported data for dose reduction of CS extractable for
CS dose reduction are 68.75% for one patient and 87.5% for the other patienpatients for each cGVHD manifestation, we could
not perform a sensitivity analysis to explore the reasons
behind the heterogeneity in the outcomes of organ-
specific responses related to cGVHD of the skin and
mucosa. This heterogeneity can be attributed to sev-
eral clinical factors, however. The patients enrolled
in these studies had a wide range of diseases and previ-
ous interventions (eg, differing conditioning regimens,
number of treatments for cGVHD before rituximab
therapy, concomitant treatment with corticosteroids
or other immunosuppressive treatments), as well as
differing criteria for assessing response rates. All of
these factors may possibly contribute to the heteroge-
neity for some of the outcomes.DISCUSSION
The totality of the evidence on the efficacy of ritux-
imab for treating steroid-refractory cGVHD demon-
strates that the skin is the most responsive organ
(Table 2) [19-22,24]. Responses were impressive in
cases of sclerodermatous or lichenoid cutaneous
cGVHD [20,22]. In the prospective study of Okamoto
et al. [22], 3 patients (100%) with sclerodermatous
cGVHD had responses occurring between 60 and 90
days from initiation of therapy. Similarly, Cutler
et al. [20] reported a decrease in median body surface
area (BSA) involved with sclerodermatous cGVHD
from 35% to 25% after 2 cycles of therapy, followed
by a further decrease to 20% at 1 year after the initia-
tion of rituximab. Cases of lichenoid cutaneous
cGVHD also responded to rituximab therapy, show-
ing a decrease in median BSA involvement from 20%
to 5% after 2 cycles and a further decrease to 3% after
1 year [20]. It is important to keep in mind that clinical
responses may continue to improve several months
after the start of rituximab. In summary, these findings
suggest that rituximab is effective in treating cutaneous
cGVHD.Therapy after Initiation of Rituximab
se
nge)
Proportion of Patients Discontinuing
Immunosuppressive Therapy(n/N)
23% (3/13)*
%) NR
NE
NA
11% (3/28)*
67% (4/6)
.5%)§ NR
re for median % dose reduction of CS for 10 patients evaluable for skin
during rituximab therapy.
2 of the 4 patients who showed a response to rituximab; the values for %
t.
Table 2. Clinical Studies Evaluating the Efficacy of Rituximab in the Setting of Steroid-Refractory cGVHD
Author, Year Study Design
Number of Patients
Enrolled
Median Age, Years
(Range)
ORR, %
Morbidity, % Mortality, % (n/N)
Dose (Median
Number of Doses)
(Cycles)
Criteria for Response
Assessment
By Organ
(Responders/Total)
TTR Days,
Median
Von Bonin et al.,
2008 [18]
Retrospective 13 60 (40-67) ORR, 69%
Skin, 56% (5/9)
Eyes, 0% (0/4)
Liver, 0% (0/3)
Gut, 0% (0/2)
Lungs, 0% (0/2)
Oral mucosa, 50%
(4/8)
Muscles, 75% (3/4)
NR Infectious
complications, 2
8% (1/13) 50 mg/m2 (weekly
intervals for 3
weeks) (3)*
National Institutes of
Health consensus
criteria†
Mohty et al.,
2008 [21]
Retrospective 15 50 (20-67) ORR, 66%
Skin, 69%
Eyes, NR
Liver, 66%
Gut, 20%
Lungs, 0% (0/2)
Oral mucosa, NA
NR Negligible 33% (5/15) 375 mg/m2 (weekly
intervals for 4
weeks) (1)
CR, PR. and organ-
specific objective
responses
Zaja et al.,
2007 [24]
Retrospective 38 48 (22-61) ORR, 65%
Skin, 63%
Eyes, 43%
Liver, 25%
Gut, 75%
Lungs, 38%
Oral mucosa, 30%
Musculoskeletal, 80%
57 days
138 days
49 days
NR
60 days
46 days
78 days
Infusion reaction, 11%
Pneumonia, 8%
Renal failure, 3%
Central nervous
system, 3%
Sepsis, 3%
21% (8/38) 375 mg/m2(weekly
intervals for 4
weeks) (1)
Differed by organ
Okamoto et al.,
2006 [22]
Prospective
( noncontrolled)
3 35 (33-42) ORR, NE
Skin, 100%
Eyes, 0% (0/3)
Liver, 0% (0/2)
Gut, NR
Lungs, 0% (0/1)
Oral mucosa, 0%
(0/2)
60-90 days Pneumonia, 33%
Sepsis, 33%
Herpes zoster, 33%
33% (1/3) 375 mg/m2 (weekly
intervals for 4
weeks) (1)
Subjective; individual
patient- based
Cutler et al.,
2006 [20]
Prospective
( noncontrolled)
28‡ 42 (21-62) ORR, 68%
Skin, (§/17)
Eyes, 0% (0/8)
Liver, NR (NR/1)
Gut, NA
Lungs, NA
Oral mucosa, 0%
(0/7)
NR Infant diarrhea, 14%
Viral conjunctivitis,
5%
Hepatitis B
reactivation, 5%
Septic arthritis, 5%
GI hemorrhage, 5%
Nephrolithiasis, 5%
Infusion reaction, 5%
11% (3/28¶) 375 mg/m2 (weekly
intervals for 4
weeks) (1)
Differed by organ;
aggregate
responses for each
organ provided
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Biol Blood Marrow Transplant 15:1005-1013, 2009 1011Rituximab in Steroid-Refractory Chronic GVHDThe response to rituximab appears to be less pro-
nounced in other organs. Cases of steroid-refractory
cGVHD of the oral mucosa showed ORRs ranging
from 0 [20,22] to 83% [19]. Similarly, clinical re-
sponses to rituximab in cases of hepatic cGVHD
ranged from 0 [18,22,23] to 66% [21]. Note that these
differing hepatic cGVHD response rates might be ex-
plained by intrinsic differences in the degree of severity
of hepatic damage resulting from cGVHD before the
initiation of rituximab, differing durations of therapy,
or the use of different criteria to measure responses
to treatment, among other factors. The time to achieve
clinical response in hepatic cGVHD was 49 days in 1
study [24]. The responses to rituximab in patients
with lung cGVHD were even less impressive, ranging
from 0% [21,22] to 38% [23,24]. It is unclear whether
the limited efficacy of rituximab in organs other than
skin is due to the treatment per se, or whether those or-
gans are more susceptible to irreversible cGVHD-im-
mune mediated damage. The underuse of more
aggressive diagnostic tools to assess organ damage be-
fore initiation of treatment, coupled with the lack of
more objective clinical tools to better quantitate clini-
cal improvement in certain organs, limit clinicians’
ability to assess the true efficacy of rituximab, or lack
thereof, in those organs.
The bona fide corticosteroid-sparing effect of rit-
uximab treatment in cGVHD resulted in a shortened
duration, or sometimes even discontination, of corti-
costeroid treatment. It is possible that this effect ulti-
mately may translate into improved quality of life for
these patients. Quality of life assessment tools should
be incorporated into prospective clinical trials to ob-
jectively address this issue.
There are several limitations to the evidence pre-
sented herein, including (1) the absence of randomized
trials; (2) the inclusion of only 3 prospective studies
that enrolled a very small number of patients
(n5 37), with none of the prospective studies clearly
reporting either the design or phase of these prospec-
tive studies; (3) the poor methodological quality of the
prospective studies (eg, none of these studies provided
details on patient enrollment, limiting our ability to as-
certain whether the study subjects were derived
through convenient sampling or consecutive enroll-
ment, to avoid selection bias); and (4) the lack of a ho-
mogeneous response criteria among studies, which
limits the ability to assess responses as a composite
or to compare responses among studies. In addition,
the retrospective studies also were limited by the rela-
tively small sample size, and none of the reports in-
cluded in this systematic review indicated whether
the analysis was intended to address an a priori hypoth-
esis or to generate a hypothesis. Several questions re-
main unanswered: What is the relationship between
response rates (and time to maximum response) and
depletion of B cell levels in relation to the number of
1012 Biol Blood Marrow Transplant 15:1005-1013, 2009M. A. Kharfan-Dabaja et al.doses of rituximab administered? Is there an additional
benefit to using higher doses of rituximab? Future clin-
ical trials should evaluate response rates at different
times in the course of cGVHD to provide a better
understanding of the pathophysiologic evolution of
cGVHD over time.
Limited understanding of the complex pathophys-
iology of GVHD remains the main barrier to develop-
ment of universally effective prophylaxis against acute
GVHD (aGVHD) and successful treatment of both
aGVHD and cGVHD. Development of antibody re-
sponses, such as allogeneic H-Y, in association with
cGVHD implicates B lymphocytes as important
players in the pathogenesis of cGVHD [20]. B lym-
phocytes play an essential role in antigen presentation
to T cells and allogeneic antibody induction, among
othermechanisms [25]. Several studies already have in-
corporated rituximab into the conditioning regimen
for patients with CD201-expressing malignancies un-
dergoing allo-HCT with encouraging results [26,27].
A BMT Clinical Trials Network is currently evaluat-
ing a multicenter phase II clinical trial (BMT CTN
protocol 0701) that combines rituximab with fludara-
bine (Flu) plus cyclophosphamide (Cy) as a nonmye-
loablative regimen for patients with relapsed
follicular non-Hodgkin lymphoma (NHL).
Earlier intervention with anti B cell therapy could
potentially reduce cGVHD-mediated irreversible or-
gan damage. Investigators at Stanford University are
currently evaluating a strategy of adding rituximab to
prednisone as front-line therapy for newly diagnosed
cGVHD, aiming to improve response while allowing
more rapid tapering of corticosteroid dosage (Clinical-
Trials.gov; identifier NCT00350545); similar studies
are underway in Europe.
It is important to understand that the totality of the
evidence generated through this systematic review
demonstrates the gaps in the existing evidence base re-
lated to the efficacy of rituximab in treating patients
with steroid-refractory cGVHD. This systematic re-
view underscores the need for well-designed and ade-
quately powered prospective studies to conclusively
address this issue.ACKNOWLEDGEMENTS
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